Family of pH (Low) Insertion Peptides for Tumor Targeting by Weerakkody, Dhammika et al.
University of Rhode Island
DigitalCommons@URI
Physics Faculty Publications Physics
2013
Family of pH (Low) Insertion Peptides for Tumor
Targeting
Dhammika Weerakkody
University of Rhode Island
Anna Moshnikova
University of Rhode Island, a_moshnikova@uri.edu
See next page for additional authors
Follow this and additional works at: https://digitalcommons.uri.edu/phys_facpubs
Terms of Use
All rights reserved under copyright.
This Article is brought to you for free and open access by the Physics at DigitalCommons@URI. It has been accepted for inclusion in Physics Faculty
Publications by an authorized administrator of DigitalCommons@URI. For more information, please contact digitalcommons@etal.uri.edu.
Citation/Publisher Attribution
Weerakkody, D., Moshnikova, A., Thakur, M. S., Moshnikova, V., Daniels, J., Engelman, D. M., Andreev, O. A., & Reshetnyak, Y. K.
(2013). Family of pH (low) insertion peptides for tumor targeting. Proceedings of the National Academy of Sciences, 110(15),
5834-5839. doi: 10.1073/pnas.1303708110
Available at: http://dx.doi.org/10.1073/pnas.1303708110
Authors
Dhammika Weerakkody, Anna Moshnikova, Mak S. Thakur, Valentina Moshnikova, Jennifer Daniels, Donald
Engelman, Oleg A. Andreev, and Yana K. Reshetnyak
This article is available at DigitalCommons@URI: https://digitalcommons.uri.edu/phys_facpubs/136
Family of pH (low) insertion peptides
for tumor targeting
Dhammika Weerakkodya, Anna Moshnikovaa, Mak S. Thakura, Valentina Moshnikovaa, Jennifer Danielsa,
Donald M. Engelmanb,1, Oleg A. Andreeva, and Yana K. Reshetnyaka,1
aPhysics Department, University of Rhode Island, Kingston, RI 02881; and bDepartment of Molecular Biophysics and Biochemistry, Yale University, New Haven,
CT 06520-8114
Contributed by Donald M. Engelman, February 27, 2013 (sent for review November 13, 2012)
Cancer is a complex disease with a range of genetic and bio-
chemical markers within and among tumors, but a general tumor
characteristic is extracellular acidity, which is associatedwith tumor
growth and development. Acidosis could be a universal marker for
cancer imaging and the delivery of therapeutic molecules, but its
promise as a cancer biomarker has not been fully realized in the
clinic. We have discovered a unique approach for the targeting of
acidic tissue using the pH-sensitive folding and transmembrane in-
sertion of pH (low) insertion peptide (pHLIP). The essence of the
molecular mechanism has been elucidated, but the principles of
design need to be understood for optimal clinical applications.
Here, we report on a library of 16 rationally designed pHLIP var-
iants. We show how the tuning of the biophysical properties of
peptide–lipid bilayer interactions alters tumor targeting, distribu-
tion in organs, and blood clearance. Lead compounds for PET/single
photon emission computed tomography and ﬂuorescence imag-
ing/MRI were identiﬁed, and targeting speciﬁcity was shown by
use of noninserting variants. Finally, we present our current un-
derstanding of the main principles of pHLIP design.
membrane-associated folding | tumor acidity | thermodynamics | kinetics |
diagnostics
The promise of exploiting tumor acidosis as a cancer bio-marker has not been fully realized in clinical practice. The
problem has been to ﬁnd a practical way to target acidity. While
studying membrane protein folding, we discovered a peptide
called pH (low) insertion peptide (pHLIP) that reversibly folds
and inserts across membranes in response to pH changes, and
this discovery has led to a unique way to target acidic tissue. Our
biophysical studies have revealed the molecular mechanism of
pHLIP action (1–3), and we have shown that pHLIP can target
acidic tissue and selectively translocate polar, cell-impermeable
molecules across cell membranes in response to low extracellular
pH (1, 4–9). pHLIP conjugated with ﬂuorescent dyes, PET [64Cu-
DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)
and 18F], single photon emission computed tomography (SPECT;
99Tc) probes, and gold nanoparticles targets acidic tumors (1, 4, 5,
10, 11). All prior studies in vivo were carried out with the WT-
pHLIP sequence and showed that a good contrast and tumor-to-
blood ratio can be achieved only more than 24 h after pHLIP
injection, when it has accumulated in the tumor and largely
cleared from the blood (5, 6). However, for the use of pHLIP-
based radioactive imaging agents in the clinic, a more rapid
background signal reduction is absolutely essential. To address
this important need, to tune tumor-targeting properties, and to
broaden our understanding of the molecular mechanism of
pHLIP action, we designed a set of 16 pHLIP variants based on
chemical and physical principles. Comprehensive biophysical
studies performed with nonlabeled peptides were correlated
with investigations of tumor targeting and organ distributions
of ﬂuorescent versions of the pHLIP variants. As a result, a set of
design criteria has been established and pHLIP candidates for
imaging and therapeutic applications, including lead compounds
for PET/SPECT imaging and ﬂuorescence imaging/MRI, have
been identiﬁed.
Results
Design of pHLIP Variants. We have reported the basic molecular
mechanism of the interaction of WT-pHLIP with lipid bilayers
(refs. 1, 2, 12). In these studies, we found three states of the pep-
tide: state I, in solution as an unstructured monomer at neutral pH
when no lipid membrane is present; state II, bound at the surface of
a lipid bilayer as a largely unstructured monomer at neutral pH;
and state III, inserted across the bilayer as a monomeric helix at
acidic pH. To broaden our understanding of the main principles of
pHLIP interactions with membranes and to select the best
sequences for clinical use, we used our knowledge and designed 16
variants of the WT-pHLIP [variant (Var) 0] sequence:
Var0-WT: ACEQNPIYWARYADWLFTTPLLLLDLALLVDADEGT
Var1: ACEDQNPYWARYADWLFTTPLLLLDLALLVDG
Var2: ACEDQNPYWRAYADLFTPLTLLDLLALWDG
Var3: ACDDQNPWRAYLDLLFPTDTLLLDLLW
Var4: ACEEQNPWRAYLELLFPTETLLLELLW
Var5: ACDDQNPWARYLDWLFPTDTLLLDL
Var6: CDNNNPWRAYLDLLFPTDTLLLDW
Var7: ACEEQNPWARYLEWLFPTETLLLEL
Var8: CEEQQPWAQYLELLFPTETLLLEW
Var9: CEEQQPWRAYLELLFPTETLLLEW
Var10: ACEDQNPWARYADWLFPTTLLLLD
Var11: ACEEQNPWARYAEWLFPTTLLLLE
Var12: ACEDQNPWARYADLLFPTTLAW
Var13: ACEEQNPWARYAELLFPTTLAW
Var14: Ac-TEDADVLLALDLLLLPTTFLWDAYRAWYPNQECA-Am
Var15: CDDDDDNPNYWARYANWLFTTPLLLLNGALLVEAEET
Var16: CDDDDDNPNYWARYAPWLFTTPLLLLPGALLVEAEET
Biophysical Studies. We studied the interaction of the pHLIP var-
iants with lipid bilayers using the ﬂuorescence and CD spectro-
scopic techniques previously used (2). The intrinsic tryptophan
ﬂuorescence and CD spectra of nonlabeled variants were mea-
sured in solution at pH 8 in the absence and presence of
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) liposomes
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and in the presence of liposomes at low pH (pH 4–5), and they
show that each peptide interacts with a lipid bilayer in a pH-
dependent manner and that the peptides form transmembrane
(TM) helices in state III (Fig. S1 and Table S1).
The partitioning of pHLIP variants into bilayers at pH 8 and
pH 4–5 was assessed in titration experiments by measuring
changes of the intrinsic peptide ﬂuorescence (Fig. 1). On aver-
age, the partitioning of the variants into the membrane at low
pH is about 50-fold higher than at high pH. As expected, the
truncated variants (Var5–13) have lower afﬁnities for the
membrane at neutral pH compared with WT and other variants,
because a number of hydrophobic residues were removed from
the sequences. In general, variants with Glu residues have
slightly higher afﬁnities compared with the same variants with
Asp residues (because Glu is more hydrophobic due to the ad-
ditional methylene group). The highest afﬁnity was observed for
Var15, which forms a helical structure at neutral pH. At low pH,
the lowest afﬁnity for the lipid bilayer was observed for the most
truncated versions Var10–13 and variants (Var15 and Var16)
with no protonatable residues in the TM, which reﬂects the re-
duced stability of the TM helix. The differences between
the Gibbs free energies (ΔGs) of the interactions of variants with
the membrane at low and high pHs (in kilocalories per mole),
ΔΔG = ΔGpH4 − ΔGpH8, are as follows:
Fig. 1. Titration of pHLIP variant binding to liposomes at high and low pHs. The titration of the pHLIP variants with increasing concentrations of POPC
liposomes at pH 8 (A) and pH 4–5 (B) is followed using intrinsic peptide ﬂuorescence changes. For comparison the mole-fraction partition coefﬁcients for Var0
(WT-pHLIP) at pH 8 and pH 5 are 4.87 × 104 and 1.54 × 106, respectively, and the corresponding ΔGs are 6.04 and 7.98 kcal/mol, respectively. The red and blue
lines are ﬁtting curves and 95% conﬁdence intervals, respectively.
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Var1 Var2 Var3 Var4 Var5 Var6 Var7 Var8
2.17 0.28 2.23 1.72 2.31 1.93 2.39 2.19
Var9 Var10 Var11 Var12 Var13 Var14 Var15 Var16
2.07 1.79 1.94 1.95 1.15 1.78 0.82 1.47
The largest differences are observed for Var3, Var5, and Var7.
The smallest differences are found for Var2 and Var15 due
to the strong interactions of these peptides with the bilayer in
state II at pH 8.
The pKa of pHLIP variant insertion was measured by follow-
ing the shift of the position of the intrinsic peptide emission
maximum as the pH is changed from pH 8 to pH 2 (Fig. 2). The
shift of pKa to lower pHs correlates with the truncation of the
pHLIP sequence: The pKa of Var10, with a single Asp residue in
its TM, is the lowest (pKa = 4.5). All variants containing Glu
residues (Var7–9, Var11, and Var13) have higher pKa values
compared with the related sequences with Asp residues (Var5–6,
Var10, and Var12).
To this point, we have considered the equilibrium energies of
progressive binding and insertion events; however, for some
applications, it is also important that sequence variation will alter
the kinetics of insertion. We have found in recent work that the
kinetics of insertion correlate with the number of protonatable
groups at the inserting end or the presence of polar cargo (13).
The characteristic membrane insertion time for WT-pHLIP is
about 30 s, and slightly faster kinetics were observed for Var14,
which is the reverse sequence of WT. Var14 has the same
number of protonatable residues at its N terminus as WT has at
its C terminus, except for the free C terminus itself. The data are
consistent with the view that the acetylated N terminus of Var14
inserts across the bilayer and the amidated C terminus stays
outside, reversing the direction of insertion. The characteristic
time of Var1–2 insertion, which has fewer protonatable residues
at its C terminus than WT, was about 1–2 s, which correlates well
with our recent ﬁndings (13). Further truncation of the peptide-
inserting end, which reduces the number of protonatable resi-
dues, resulted in faster peptide insertion, completed within ﬁrst
30–100 ms for Var3–13. There are no protonatable residues in
the TM in Var15–16, although they have the same number of
Asp/Glu residues as WT at the inserting end; as a result, the time
of insertion was reduced to 10–11 s relative to WT. The kinetics
data are shown in Fig. 3.
Tumor Targeting and Distribution of Alexa750-pHLIPs in Organs. We
used a mouse xenograft model to assess the tumor targeting and
organ distribution of the pHLIP variants. Tumors were created
by s.c. injection of HeLa-GFP cancer cells in the right ﬂanks of
each mouse, and they were grown to about 5 mm in diameter. To
perform biodistribution studies, pHLIP variants were conjugated
with Alexa750. We demonstrated that the kinetics of insertion
of Alexa750-WT-pHLIP into lipid bilayers are similar to the
kinetics of insertion of nonlabeled peptide (Fig. S2). Fluorescently
labeled pHLIPs were given as single i.v. injections, and the major
organs and tumors were collected at 4 and 24 h after ﬂuorescent
pHLIP administration. The GFP and near infrared (NIR) signals
were monitored in tumors and organs after killing the mice. The
mean intensities of NIR ﬂuorescence normalized to the signal in
kidneys at 4 h are shown in Fig. S3. The mean intensities of NIR
ﬂuorescence of all organs and the number of mice used in the
study for each variant are given in Tables S2 and S3.
The pHLIP variants that show higher afﬁnities for membranes
at high pH have higher short-term liver uptake (Var1, Var2,
Var4, and Var14–16); however, the liver is cleared at 24 h, except
for Var1. Var3 has high tumor targeting compared with kidney
and compared with other pHLIPs as well. Whole-body and organ
imaging conﬁrmed that the truncated variants Var5–13 have
much faster blood clearance than WT; at 4 h, the signal has
accumulated in the tumor, although being washed out of the
organs. Tumor targeting was minimal for the shortest pHLIP
variants Var12–13. The tumor/muscle, tumor/kidney, and tumor/
liver ratios are given in Fig. 4 for all pHLIP variants calculated at
4 and 24 h after injection. Var0, Var3–4, and Var14–16 have the
highest tumor/muscle ratio at 24 h. The same pHLIP variants
have the highest tumor/kidney ratios, whereas only Var3 shows
signiﬁcantly less accumulation in the liver. Among the truncated
pHLIP variants, Var7 demonstrates the highest tumor targeting.
This body of work allows us to propose different pHLIP var-
iants for different applications. We have selected Var3 and Var7
as the best candidates for future studies for ﬂuorescence imag-
ing/MRI and PET/SPECT imaging, respectively, guided by the
fact that the imaging time window for the stable ﬂuorescence and
MRI agents can be much wider than for the short t1/2 of PET and
SPECT agents. Var3 had the highest tumor/organ ratios, espe-
cially at 24 h after construct administration. Var7 had a lower
tumor/organ ratio but showed much faster blood clearance. The
cytotoxicity of the selected pHLIP variants was evaluated on
human cervix adenocarcinoma (HeLa) and human lung carci-
noma (A549) cells, as well as on human cervical (HCvEpC),
Fig. 2. pH-dependent bilayer insertion of variants. Peptide intrinsic ﬂuo-
rescence changes are used to follow the insertion as a function of pH
(transition from state II to state III as the pH is lowered). The red and blue
lines are ﬁtting curves and 95% conﬁdence intervals, respectively.
Fig. 3. Kinetics of insertion. Representative kinetic curves for the insertion
of variant peptides into the lipid bilayer are shown. The characteristic time
of insertion of Var0 (WT-pHLIP) is about 40 s.
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mammary (HMEpC), and bronchial (HBEpC) epithelial cells.
Peptides at concentrations of up to 8 μM were evaluated at up to
72 h of incubation with cells, and no toxicity was observed.
pH-Insensitive K-pHLIPs. As a control, we have previously used
K-pHLIP-WT, where the two key D (Asp) residues in the TM part
of the peptide were replaced by K (Lys) residues (1). K-pHLIP
cannot interact with a membrane in a pH-dependent manner over
the range of neutral and low pHs we are studying; therefore, it
should not target acidic tumors. Because of the potential clini-
cal applications of Var3 and Var7, we synthesized and tested
K-versions of each:
K-Var3: ACDDQNPWRAYLKLLFPTKTLLLKLLW
K-Var7: ACEEQNPWARYLKWLFPTKTLLLKL
Each of these peptides failed to interact with lipid bilayers in
a pH-dependent fashion (Fig. 5 A and B). No shift in the position
of the peptide ﬂuorescence maximum was seen for either of the
K-pHLIPs in the presence of lipid as a result of pH decrease, and
the CD spectra do not change and do not exhibit the minima at
208 and 225 nm that are characteristic signals reporting α-helical
conformations. The CD spectra reveal a negative band at 234 nm
and a positive band at 221 nm, suggestive of an exciton split dou-
blet (2, 14) possibly arising from peptide aggregation.
Var3 and Var7, as well as K-Var3 and K-Var7, were conju-
gated with two different ﬂuorescent dyes, zwitterionic tetrame-
thylrhodamine (Rho) and noncharged boron-dypyrromethene
(BODIPY), to ensure that distribution and localization of ﬂuo-
rescent peptides is independent of the choice of dye. The ﬂuo-
rescence images demonstrating cellular uptake of Rho- and
BODIPY-labeled Var3, Var7, K-Var3, and K-Var7 are shown in
Fig. 5 C and D and Fig. S4, respectively. The ﬂuorescence signal
of cells treated with ﬂuorescent Var3 and Var7 at pH 7.4 was
weaker compared with that of cells treated with peptides at pH
5.9. The cellular uptake of Var3 was 1.12-fold higher at low pH
Fig. 4. Tumor-to-organﬂuorescence ratios. Tumor-to-muscle, tumor-to-kidney,
and tumor-to-liver ratios calculated at 4- and 24-h time points are shown for all
pHLIP variants.
Fig. 5. Comparisons with control K-pHLIPs. The CD (A) and tryptophan ﬂuo-
rescence (B) spectra of K-Var3 and K-Var7 show that these variants lose the
ability to interact with a lipid bilayer in a pH-dependent manner. (C and D)
Cellular uptake at pH 7.4 and pH 5.9 of peptides labeled with rhodamine
is shown. The images were obtained under an inverted optical microscope with
a 60× objective. The cellular uptake of peptides labeled with BODIPY is shown
at both pHs in Fig. S4.Whole-body NIR ﬂuorescence images ofmice obtained at
4 and 24 h after i.v. administration of Var3 and K-Var3 (E) and Var7 and K-Var7
(F) conjugated with Alexa750 are shown. The tumors are indicated by arrows.
Images obtained at different time points are presented with maximum con-
trast; the contrast-to-noise ratios are as follows: Var3, 4 h = 103; Var3, 24 h =
186; Var7, 4 h= 85; Var7, 24 h= 360; K-Var3, 4 h= 87; K-Var3, 24 h= 54; K-Var7,
4 h = 22; and K-Var7, 24 h = 16. (G) A549-GFP tumor-to-muscle ratios calculated
for 4 h for BODIPY-pHLIPs and BODIPY-K-pHLIPs and HeLa-GFP tumor-to-
muscle ratios calculated for 4- and 24-h time points for Alexa750-pHLIPs and
Alexa750-K-pHLIPs are shown. The mean ﬂuorescence of HeLa-GFP and A549-
GFP tumors and organs at 4 and 24 h after administration of Alexa750-K-
pHLIPs and at 4 h after administration of BODIPY-pHLIPs and BODIPY-K-pHLIPs
are given in the Tables S4 and S5, respectively.
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compared with neutral pH, and uptake of Var7 was 1.34-fold
higher at low pH. Our biophysical data show that the afﬁnity of
Var3 for a membrane at pH 8 is higher than the afﬁnity of Var7
at the same pH; therefore, we see slightly higher cellular uptake
of Var3 at pH 7.4 compared with Var7 and a less pronounced
difference in cellular uptake between neutral and low pHs for
Var3. For the cases of K-Var3 and K-Var7, the ﬂuorescence
signal was very similar when cells were treated at either high or
low pH; moreover, the ﬂuorescence signal at pH 7.4 was slightly
higher than at pH 5.9. Also, the distributions of ﬂuorescent signals
for D (Asp)- and E (Glu)-variants and K (Lys)-variants were
different. K-Var3 and K-Var7 were distributed as cytoplasmic
dots. In contrast to pHLIP variants, K-pHLIPs are positively
charged and partially aggregated, and, most probably, they might
be taken up by endocytosis and trapped in endosomes in a pH-
independent manner, whereas cellular uptake of Var3 and Var7
is pH-dependent.
Biodistribution and tumor targeting of Alexa750-K-pHLIPs
were also investigated using xenograft models in mice. In con-
trast to Var3 and Var7, K-pHLIPs did not show signiﬁcant tumor
targeting (Fig. 5 E and F and Table S4). To demonstrate that
tumor targeting by Var3 and Var7 and the lack of tumor tar-
geting by K-Var3 and K-Var7 are independent of the choice of
tumor model and imaging ﬂuorescent probe, we used BODIPY-
labeled Var3, Var7, K-Var3, and K-Var7, which were tested on
tumors created by s.c. injection of A549-GFP human lung car-
cinoma cells. The organs were collected at 4 h and analyzed
(Table S5). The tumor-to-muscle ratio at 4 h for Var3 and Var7
labeled with BODIPY and Alexa750 was 6.0 ± 0.9, whereas for
K-Var3 and K-Var7, it was 2.6 ± 0.3 (Fig. 5G). Thus, the re-
placement of the Asp/Glu residues by Lys in the TMs of Var3
and Var7 leads to the loss of both pH-dependent interactions
with membranes and targeting of acidic tumors, supporting
a central role for the carboxyl groups in targeting. However, we
note that although K-pHLIPs may be considered as controls for
in vitro studies, they should be used with caution in vivo, because
the positive charges of K-pHLIPs might promote interactions
with receptors and endocytotic uptake, which might vary for
different tumor types.
Discussion
An acidic extracellular milieu favors tumor growth, invasion, and
development (15–20), and the pHLIP peptides can exploit tumor
acidity as a useful biomarker. Based on the results of our pre-
vious and current investigations, design principles can be for-
mulated to set directions for different clinical uses:
The apparent pK of insertion of a pHLIP into a membrane
depends on a combination of the pKs of protonation of all
protonatable groups. Each pK of protonation of a carboxyl
group depends on its environment, and it is increased as the
surrounding dielectric constant is lowered. Thus, carboxyl pKs
will be gradually raised with peptide propagation deeper into
the membrane. The pKa of peptide insertion determines the
proportion of available peptide molecules inserted into the
plasma membrane of cancer cells at various pHs. Currently,
we have pHLIP peptides with pKs varying over the range from
4.5 to 6.5 for insertion into POPC lipid bilayers. Various
pHLIP variants might be used to probe the pHs of more or
less acidic tumors. The insertion of pHLIP responds to the pH
at the surfaces of cancer cells rather than that of the surround-
ing ﬂuid, because the TM potential gradient causes protons
to accumulate at the surfaces of cells and the pH is lower
than in the bulk extracellular environment or in the blood.
Current methods of measuring pH in vivo report the average
value of the extracellular pH in tumors, which can vary from
6.0 to 7.2, but the pHs at the surfaces of cancer cells are likely
to be lower. Moreover, the cellular pH gradient observed in
tumors will favor cell entry of compounds with pKs in range of
4.5–6.5 (21, 22).
pHLIP is a relatively hydrophobic peptide; therefore, signiﬁ-
cant initial association with a lipid bilayer or plasma mem-
brane occurs at neutral pH. The strength of this interaction
(state II) is determined by the balance between hydrophobic
and polar/charged residues in the pHLIP sequence. Stronger
partitioning of the peptides onto bilayers at neutral pH increases
the time of circulation in the blood, because the pHLIPs
bind to the surface of blood cells. A long circulation time is
a disadvantage for PET/SPECT imaging, because short t1/2
time probes are used and tumor targeting and blood clearance
need to be very fast (preferably within 4 h). However, long
circulation times of pHLIP variants in the blood may be well
suited for ﬂuorescence or MR imaging, as well as for the de-
livery of therapeutic agents. We ﬁnd that all pHLIP variants
that have higher afﬁnities for membranes at neutral pH show
high tumor/organ ratios at 24 h postinjection.
An important parameter is the difference between the ΔΔG of
peptide binding to membranes at low pH vs. high pH. This
parameter reﬂects the difference in the afﬁnity of the peptide
to the membrane at low and neutral pHs, as well as the
strength of formation of the TM helix at low pH. A larger
ΔΔG will ensure a greater differentiation between the inserted
and noninserted peptides as a function of pH.
For applications in vivo, the kinetics of peptide insertion
across the lipid bilayer are important for rapid equilibration
with tissues and clearance from the blood. Based on inser-
tion kinetics, we can group all pHLIP peptides into the fol-
lowing: (i) Peptides with protonatable residues both in
the TM and in the inserting end show the slowest kinetics
of insertion (minutes); (ii) peptides that are truncated at
the inserting end and have few or no protonatable residues
at the inserting end partition in bilayer much faster (sec-
onds); (iii) peptides that have protonatable residues at the
inserting end but not in the TM show intermediate times of
insertion (∼20 s); and (iv) peptides with only one protonat-
able residue in the TM have the fastest kinetics of insertion,
which coincide with the time of formation of the helical
structure (∼100 ms).
Exit kinetics should be different in cells and liposomes, be-
cause peptides that have protonatable residues translocated
across a cell membrane move them to the neutral pH of the
cytoplasm. To exit the cell membrane, these groups must be
protonated, which is much less likely in the cytoplasm; thus,
these peptides become anchored in a cell. Such an “anchor”
can signiﬁcantly (by orders of magnitude) reduce the rate of
peptide exit, and the peptide could stay in the plasma mem-
brane for weeks. Such an effect would explain our observa-
tion that mouse tumors are stably labeled with ﬂuorescent
WT-pHLIP.
We have selected two pHLIP variants for further trans-
lational development (in addition to WT-pHLIP): Var3 and
Var7. Var3 demonstrates high tumor-to-organ ratios at 24 h
(similar to WT) and could be well suited for optical imaging
or MRI 1 d after administration. Var3 might also be suitable
for ﬂuorescence-guided surgery, marking a tumor with ﬂuo-
rescently labeled pHLIP and performing surgery on the next
day, when the contrast index is the highest. Var7 is one of the
truncated versions of pHLIP, which could be appropriate for
PET/SPECT imaging, because it demonstrates fast tumor tar-
geting and blood clearance.
Materials and Methods
The details of experimental protocols can be found in SIMaterials andMethods.
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Materials. pHLIP variants were prepared by solid-phase peptide synthesis
at the W. M. Keck Foundation Biotechnology Resource Laboratory at Yale
University. Variants were conjugated with malemides of the dyes: Alexa750,
Rho, or BODIPY. The purity of products was assessed by analytical HPLC, and
peak identity was conﬁrmed by surface-enhanced laser desorption/ionization
TOF MS. Large unilamellar POPC (Avanti Polar Lipids, Inc.) vesicles were
prepared by extrusion.
Steady-State Fluorescence and CD Measurements. Peptide ﬂuorescence spec-
tra were recorded with the spectral widths of excitation and emission slits
set at 4 and 2 nm, respectively, using excitation wavelengths of 295 or
280 nm. The concentrations of the peptides and POPC liposomes were 7 μM
and 1.5 mM, respectively.
Oriented CD Measurements. Oriented CD was measured from the supported
bilayers deposited on a stack of quartz slides with special polish for far UV
measurements as described previously (13).
Titration Experiments. The intrinsic ﬂuorescence spectra of samples containing
5 μM peptides and varying concentrations of lipids were measured using
280-nm excitation at 25 °C, with the emission polarizer set at 90°. The
titration data were ﬁtted by the peptide-membrane partition model to
calculate the mole-fraction partition coefﬁcient.
pH Dependence. The pH-dependent partitioning of the peptides into lipid
bilayers was investigated by the shift of the position of the peptide intrinsic
ﬂuorescence spectral maximum for the pHLIP variants induced by a drop
of pH from pH 8 to pH 3 by means of the addition of HCl in the presence
of POPC liposomes. Peptide (3 μM) was incubated overnight with 100 nm of
POPC liposomes (2 mM), and the pH was decreased by the addition of
aliquots of 4, 2, 1, and 0.1 M HCl. The data were analyzed using the Henderson–
Hasselbalch equation.
Stopped-Flow Fluorescence Measurements. Stopped-ﬂow ﬂuorescence mea-
surements were carried out on an SFM-300 mixing apparatus (Biologic, Inc.)
connected to a spectrometer. All solutions were degassed for several
minutes under vacuum before loading into the syringes of the stopped-ﬂow
apparatus to minimize air bubbles. pHLIP variants (7 μM) were preincubated
with POPC (1.5 mM) at pH 8.0 to reach binding equilibrium, and insertion
was induced by fast mixing (5-ms dead time) of equal volumes of pHLIP-
POPC variants at pH 8.0 and appropriately diluted HCl to obtain a drop of pH
from 8 pH to the desired value.
Cell Lines. Human cervix adenocarcinoma (HeLa and HeLa-GFP cells) and lung
carcinoma (A549 and A549-GFP cells), HCvEpCs, HMEpCs, and HBEpCs were
used in studies.
Fluorescence Microscopy. HeLa-GFP and A549-GFP cells were incubated with
2 μM Rho- or BODIPY-labeled Var3, K-Var3, Var7, or K-Var7 peptide at pH
5.9 or pH 7.4. After 30 min of incubation, cells were washed four to ﬁve
times and ﬂuorescent images were acquired.
Quantiﬁcation of Cellular Uptake. For quantiﬁcation of cellular uptake of
BODIPY-labeled Var3 and Var7 at pH 7.4 and pH 5.9, we used A549-GFP cells
in suspension. Fluorescently labeled peptides (2 μM) were incubated with
cells in DMEM media at pH 7.4 and pH 5.9 for 30 min at 37 °C and 5% (vol/
vol) CO2 and 95% (vol/vol) air. Cells were then pelleted by centrifugation
and resuspended, and ﬂuorescent signals were measured and analyzed
using the ImagePro Plus program (Media Cybernetics, Inc.).
Cytotoxicity Assay. The increasing amounts of pHLIP variants (1, 2, 4, and
8 μM) were added to HCvEpCs, HMEpCs, or HMEpCs, or growth medium was
replaced with the medium without FBS containing increasing amounts of
pHLIP. After 3 h of incubation, an equal volume of the medium containing
20% FBS was added in the case of HeLa and A549 cells. After 24, 48, and 72 h
of incubation, a colorimetric reagent (CellTiter 96 AQueous One Solution
Assay; Promega) was added for 1 h, followed by measuring absorbance at
490 nm to assess cell viability.
Animal Studies. In total, 266 athymic female nude mice were used in the
experiments. Mouse tumors were established by s.c. injection of HeLa-GFP
or A549-GFP cells (106 cells per 0.1 mL per ﬂank) in the right ﬂank of each
mouse. When tumors reached 5–6 mm in diameter, tail vein injections of
100 μL of Alexa750-pHLIPs (40 μM) were performed. Animals were im-
aged at 4 and 24 h postinjection on an FX Kodak in vivo image station
under gas anesthesia, with supplemental heat provided to maintain core
body temperature. Animals were euthanized at 4 or 24 h, and a necropsy
was performed immediately after euthanization. Tumors and major
organs were collected for further imaging. All animal studies were con-
ducted according to the University of Rhode Island Institutional Animal
Care and Use Committee animal protocol (AN07-01-015), in compliance
with the principles and procedures outlined in the National Institutes of
Health Guide for the Care and Use of Animals.
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